Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
| Inventor | Institute |
|---|---|
| Ayham Alnabulsi | Vertebrate Antibodies Limited |
| Cat. #: | 152164 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell signaling and signal transduction;Metabolism;Tissue-specific biology |
| Application: | ELISA ; IHC ; WB |
| Target: | Cytochrome P450 2A6, 2A7and 2A13 (CYP2A6, CYP2A7, CYP2A13) |
| Reactivity: | Human |
| Clone: | F16 P2 D8 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Immunogen: | ovalbumin-conjugated synthetic peptide RNYTMSFLPR. CYP2A6, CYP2A7and CYP2A13 have the same c-terminal sequence. (C-terminal sequence identical in human and rhesus macaque) |
| Target background: | Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Murray et al. 2010. Histopathology. 57(2):202-11. PMID: 20716162. Profiling the expression of cytochrome P450 in breast cancer. Downie et al. 2005. Clin Cancer Res. 11(20):7369-75. PMID: 16243809. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Kumarakulasingham et al. 2005. Clin Cancer Res. 11(10):3758-65. PMID: 15897573. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.